menu
    • menu
    [{"orgOrder":0,"company":"FarmaMondo","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Cenegermin","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"FarmaMondo \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"FarmaMondo \/ Domp\u00e9 farmaceutici"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"FarmaMondo \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"FarmaMondo \/ Helsinn Group"}]

    Find Clinical Drug Pipeline Developments & Deals by FarmaMondo

    Menu

    FarmaMondo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            FarmaMondo

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            FarmaMondo

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Helsinn Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO® In The Baltic Region

                            Details : Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in ...

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Helsinn Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            FarmaMondo

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            FarmaMondo

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Dompé and The FarmaMondo Group Enter Agreement to Distribute Oxervate in Russia and Other CIS Countries

                            Details : Dompé farmaceutici and FarmaMondo have inked Managed Access Program distribution agreement appointing the FarmaMondo as the exclusive partner to make Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis in Russia and other ...

                            Brand Name : Oxervate

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 26, 2020

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth